X4 Pharmaceuticalsの空売り状況は、投資家がX4 Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

X4 Pharmaceuticals (NASDAQ:XFOR) 株価情報, 空売り情報

X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc Warrants (12/04/2024)

<ul>
<li>JetCool's SmartSense Coolant Distribution Unit (CDU) liquid-to-liquid solutions support hyperscale, enterprise, and colocation applications</li>
<li>Supported by Flex's advanced manufacturing capabilities and services to enable customers to rapidly scale liquid cooling infrastructure</li>
<li>Flex will highlight the CDU at the 2025 OCP EMEA Summit in booth A18</li>
</ul>

News

FLEX

Flex Expands JetCool Portfolio With In-Rack SmartSense CDU Delivering Up To 300kW Per Rack

In summary:
<ul>
<li>We urge shareholders not to be misled by the Vivo group's attempts to relitigate an unappealable verdict by the Privy Council, rewrite history, and paint a fictitious picture of the last few years' events, while simultaneously attempting to line their own pockets at your expense.</li>
<li>It is our fiduciary duty to vigorously defend against the hostile actions and lawsuits by the Vivo group so that we may ensure fairness for all shareholders, restore integrity and trust, and position SINOVAC for the future.</li>
<li>We are confident we will prevail, and we want to emphasize that we are urgently working to make things right as soon as possible to mitigate against further chaos and litigation, after what we have all endured over the last seven years.</li>
</ul>

SINOVAC Board Responds To Vivo Capital's Legal Threats, Defends $55/Share Special Dividend For Common Shareholders

General

NTRS

Northern Trust Inks Service Agreement With Ecosystem Certification Organization (ECO) To Provide Recordation And Settlement Services For Digital Carbon Credit Units Issued To Project Developers Under The Natural Forest Standard (NFS)

As part of the carve-out transaction, the management team and all employees currently operating the EMEA colocation business within STACK are expected to migrate with the Company, which will be re-branded and will no longer bear the "STACK Infrastructure" name or logo. STACK will continue its growth trajectory with a focus on hyperscale development and operations across key EMEA markets

Apollo To Acquire Seven-Asset European Colocation Portfolio From STACK Infrastructure In Strategic Carve-Out Transaction

<figure class="table"> 
<table>
<tbody>
<tr>
<td>REAFFIRMING FY25 GUIDANCE[1,4]</td>
</tr>
</tbody>
</table>
</figure>
Outlook for FY25 reflects our current assessment of market conditions. Unless stated otherwise, guidance is on an adjusted comparable[4] &amp; FX-neutral basis.
Revenue: growth of approx.~4%
Balanced between volume &amp; revenue per unit case
Two fewer selling days in Q1, one extra in Q4
Cost of sales per UC: comparable growth of ~2%
Expect broadly flat commodity inflation (hedged at ~90% for FY25)
Concentrate directly linked to revenue per UC through incidence pricing
Operating profit: growth of ~7%
Comparable effective tax rate: ~26%
CAPEX: ~5% of revenue (incl. leases)
Comparable free cash flow: at least €1.7bn
Dividend payout ratio: ~50%[7] based on comparable EPS
Share buyback: €1bn over 12 months from February 2025

Earnings

Guidance

Coca-Cola European Partners plc Ordinary Shares

CCEP

Coca-Cola Europacific Partners Reaffirms FY25 Outlook With ~4% Revenue Growth, ~7% Profit Increase, 2% Cost Inflation, And €1.7B+ Free Cash Flow

Coca-Cola Europacific Q1 Revenue €4.689B (+5% YoY), Adjusted Comparable Volume -0.8%

The President Donald Trump administration&#8217;s request for Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) to conduct new clinical trials for its COVID-19 vaccine.
What Happened: Novavax announced Monday that the Food and Drug Administration requested a new clinical trial before granting full approval for its protein-based COVID-19 shot, despite the company believing its vaccine remains &#8220;approvable.&#8221; 
The requirement came shortly after FDA Commissioner Marty Makary characterized the annually updated vaccine as &#8220;a new product&#8221; requiring new studies.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">To be clear, this is a new product that Novavax is trying to introduce to the market with a study of a different product from 2021. New products require new clinical studies. Under this administration, we are prioritizing the Gold Standard of Science&#8211;not what saves pharma… <a href="https://t.co/1f7NvJ9qEJ">pic.twitter.com/1f7NvJ9qEJ</a>
&mdash; Dr. Martin Makary (@DrMakaryFDA) <a href="https://twitter.com/DrMakaryFDA/status/1916253910039429309?ref_src=twsrc%5Etfw">April 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The situation developed following leadership changes at the FDA, including the departure of the agency&#8217;s longtime Vaccine Chief over disagreements with Health Secretary Robert F. Kennedy Jr. 
Industry experts note the FDA had been on track to approve Novavax&#8217;s application by April 1, but Trump appointees directed a pause, the Associated Press <a href="https://apnews.com/article/vaccine-novavax-fda-trump-covid-study-4b4465ad77cfb0554b27b7d59c40ae32">reported</a>, citing anonymous sources.
See Also: <a href="https://www.benzinga.com/general/entertainment/25/04/45059675/mrbeast-sparks-outrage-with-100-men-vs-gorilla-post-on-elon-musks-x-peta-claps-back-try-100-reasons-to-leave-animals">MrBeast Sparks Outrage With &#8216;100 Men Vs Gorilla&#8217; Post On Elon Musk&#8217;s X — PETA Claps Back: &#8216;Try 100 Reasons To Leave Animals&#8230;&#8217;</a>
Why It Matters: A United States Department of Health and Human Services spokesman suggested all COVID-19 vaccines could face stricter requirements, stating: &#8220;The urgency to rush approval of boosters without normal oversight no longer exists.&#8221;
Preliminary results from <a href="https://www.benzinga.com/general/biotech/25/04/44824383/novavax-covid-vaccine-shows-milder-side-effects-than-pfizer-biontechs-shot-study">the SHIELD-Utah study</a> showed Novavax&#8217;s 2024-2025 formula targeting the JN.1 strain produced fewer and less severe side effects compared to Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and BioNTech SE&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) mRNA shots.
Former Health Secretary Xavier Becerra defended the safety record of COVID-19 vaccines, noting: &#8220;We had put some 700 million COVID vaccines into the arms of Americans. That&#8217;s a pretty good size clinical trial.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/insider-trades/25/04/45059696/airbnb-billionaire-joe-gebbia-buys-over-1-million-worth-of-tsla-stock-ahead-of-elon-musks-robotaxi-launch-in-june">Airbnb Billionaire Joe Gebbia Buys Over $1 Million Worth Of TSLA Stock Ahead Of Elon Musk&#8217;s Robotaxi Launch In June</a></li>
</ul>
Image Via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Health Care

Markets

BNTX

MRNA

NVAX

Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline

The Chinese commerce ministry stated that U.S.-imposed tariffs have adversely affected Chinese airlines and Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>). The ministry has called on Washington to consider the grievances of these companies and promote a stable trade environment.
What Happened: This marks Beijing&#8217;s first remark on the tariffs&#8217; impact on the aviation sector since Boeing returned three 737 MAX planes, initially stationed in China for delivery to Chinese customers, back to the U.S,, Reuters reported on Tuesday.
Last week, Boeing disclosed that due to the tariffs, multiple Chinese customers have refused to accept delivery of new planes, leaving the company to find new buyers for potentially dozens of aircraft. Beijing has also signaled concern over the consequences of the trade war.
The ministry underscored China&#8217;s readiness to back normal business collaboration between the two countries and urged&nbsp;Washington to create a predictable&nbsp;trade and investment environment. &#8220;China&#8217;s&nbsp;affected airlines and Boeing have&nbsp;suffered greatly,&#8221; the ministry noted, emphasizing that the U.S. tariffs have&nbsp;disrupted global supply chains, air&nbsp;transport, and investment activities.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/04/45038824/treasury-secretary-scott-bessent-says-its-up-to-china-to-de-escalate-trade-tensions-india-to-be-the-first-trade-d" target="_blank" rel="noreferrer noopener">Treasury Secretary Scott Bessent Says It&#8217;s Up To China To &#8216;De-Escalate&#8217; Trade Tensions, India To Be The &#8216;First Trade Deal&#8217; To Be Signed</a>
Why It Matters: Beijing recently instructed Chinese airlines to halt new Boeing orders and get approval for pending deliveries, making the company the latest U.S. firm affected by the U.S.-China trade war. 
The U.S. tariffs have led to a significant <a href="https://www.benzinga.com/markets/equities/25/04/45032435/trump-tariffs-prompt-suspension-of-chinese-factory-operations-and-shift-to-new-markets">disruption </a>in the global supply chain. This development has had a ripple effect across global supply chains and threatened millions of jobs. Chinese manufacturers have had to suspend operations and seek alternative markets due to the impact of these tariffs. The country is also at risk of losing nearly 16 million manufacturing jobs amid the escalating trade tensions, as per Goldman Sachs.
Nevertheless, in a bid to ease trade tensions, China has begun <a href="https://www.benzinga.com/news/global/25/04/45004954/china-reportedly-begins-exempting-key-us-imports-from-tariffs-including-pharma-and-aerospace-parts">exempting </a>some U.S. imports from high tariffs. Companies in China have been asked by officials to identify essential U.S. goods that are difficult to replace. Some pharmaceutical imports and aerospace&nbsp;parts, including engines and landing&nbsp;gear, have already been exempted from the 125% tariffs. French aircraft engine maker, Safran confirmed that China granted tariff exemptions on certain aerospace equipment parts, including engines and landing gear.
Boeing closed 2.44% higher on Monday <a href="https://www.benzinga.com/25/04/45047782/boeing-stock-jumps-on-bernstein-upgrade-is-the-company-back-on-track">following </a>Bernstein's upgrade of the stock from a Market Perform to an Outperform rating and an increase in its price target from $181 to $218.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/events/25/04/44971154/trump-fails-to-impress-americas-young-shows-poll-as-they-still-favor-biden-only-15-think-us-on-right-track" target="_blank" rel="noreferrer noopener">Trump Fails To Impress America&#8217;s Young, Shows Poll As They Still Favor Biden — Only 15% Think US On Right Track &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Economics

China Breaks Silence On Tariff Impact, Says Trump Policies Are Hurting Its Airlines And Boeing

<ul>
<li>European Commission converts conditional approval of FILSPARI (sparsentan)&nbsp;into standard marketing authorization for the treatment of IgA Nephropathy (IgAN)</li>
<li>Decision follows positive recommendation from Committee for Medicinal Products for Human Use (CHMP) from February 2025</li>
<li>EU approval is based on the complete data set from the phase-III PROTECT study</li>
</ul>

TVTX

Reported Earlier, CSL Vifor And Travere Secure Standard EU Approval For FILSPARI In IgA Nephropathy Following CHMP Recommendation

<ul>
<li>HTWO Energy Savannah will serve Hyundai's new Hyundai Motor Group Metaplant America (HMGMA), utilizing XCIENT hydrogen heavy-duty fuel cell trucks for Clean Logistics</li>
<li>Phase one to create a scalable Class-8 hydrogen refueling solution, in collaboration with HTWO Logistics (Fleet Operations), HydroFleet (Hydrogen Refueling), and Capital Development Partners (Overall Development)</li>
<li>Phase two plans include commercial vehicle electric charging capability</li>
<li>HTWO Energy Savannah marks a significant step forward in the decarbonization of emissions-intensive port operations and major logistics corridors</li>
</ul>

HYMTF

Reported Earlier, Hyundai Announces HTWO Energy Savannah To Power Zero-Emission Heavy-Duty Trucking Near Port Of Savannah

The funds from this operation are intended to be allocated to non-investment expenses, in accordance with the Resolution issued by the MHCP and the company's 2025 financing plan and help reach the Gross Debt/EBITDA target for the year.

Reported Earlier, Ecopetrol Secures Ministry Authorization For $500M Loan Agreement With Banco Santander

Gerdau (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GGB#NYSE">GGB</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.10 by 37 percent. This is a 42.73 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $2.97 billion which beat the analyst consensus estimate of $2.57 billion by 15.45 percent. This is a 9.40 percent decrease over sales of $3.27 billion the same period last year.

Earnings Beats

Earnings Misses

Gerdau Q1 EPS $0.06 Misses $0.10 Estimate, Sales $2.97B Beat $2.57B Estimate

Reported Earlier, Telix Gains French Approval For Illuccix, Expanding Access To PSMA-PET Imaging For Prostate Cancer Diagnosis And Management

TACT

Reported Earlier, TransAct Technologies Powers Digital Transformation With Successful BOHA! Terminal 2 Deployment Across 1,400 Convenience Store Locations

Billionaire Joe Gebbia, co-founder of Airbnb Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), has purchased over 4000 Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stocks.
What Happened: Gebbia, who is a member of the company's board of directors, purchased 4000 shares at $256.308, as revealed by an SEC filing on Monday.
Gebbia has been on Tesla's board as an independent director since 2022. He also <a href="https://www.benzinga.com/25/03/44265658/billionaire-airbnb-founder-works-with-elon-musk-at-doge">joined Elon Musk's DOGE</a>, or Department of Government Efficiency, to work on the government's paper-based retirement process.
Why It Matters: The news comes in as Tesla is gearing up for its robotaxi launch in June, which Musk shared at the Q1 earnings call, could feature<a href="https://www.benzinga.com/news/earnings/25/04/44943387/elon-musk-shares-fsd-update-at-tesla-earnings-call-10-to-20-model-ys-will-offer-paid-robotaxi-rides-in-june"> 10 to 20 Model Ys</a> deployed on the first day of operations.
The billionaire also reiterated at the earnings call that he would scale back on his DOGE duties to focus on Tesla, which led to analysts like <a href="https://www.benzinga.com/25/04/44945402/wedbushs-dan-ives-raises-teslas-price-target-to-350-as-musk-promises-to-significantly-reduce-doge-time">Dan Ives setting high price targets</a> on Tesla Stock, as well as the stock itself surging in value.
However, Tesla has been grappling with its fair share of problems, including <a href="https://www.benzinga.com/tech/25/04/44857987/tesla-experiences-151-decline-in-new-vehicle-registrations-in-california-report">declining sales figures </a>in the U.S. <a href="https://www.benzinga.com/25/04/44975755/tesla-sales-decline-28-in-europe-as-ev-car-market-experiences-growth-report">as well as Europe</a>, and a 71% YoY profit plunge for Q1 2025, which showcases what was a difficult quarter for the EV giant. Tesla owners in the U.S. are also battling declining used car values as well as rising insurance premiums amid bouts of vandalism.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="205" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031459/TSLA-1024x205.jpg" alt="" class="wp-image-892178" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031459/TSLA-1024x205.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031459/TSLA-300x60.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031459/TSLA-768x154.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031459/TSLA-1536x307.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031459/TSLA.jpg 1646w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
TSLA scores well on Momentum and Quality metrics, and has a satisfactory Growth score. However, the stock scores poorly in Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge</a> today!
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/45002938/tesla-bull-gary-black-says-robotaxi-experiment-in-austin-with-10-20-cars-does-not-warrant-billions-in-valuation-potential">Tesla Bull Gary Black Says Robotaxi &#8216;Experiment&#8217; In Austin With &#8217;10-20&#8242; Cars Does Not Warrant Billions In Valuation Potential</a></li>
</ul>
Image Via Shutterstock

Insider Trades

Tech

ABNB

TSLA

Airbnb Billionaire Joe Gebbia Buys Over $1 Million Worth Of TSLA Stock Ahead Of Elon Musk's Robotaxi Launch In June

Jimmy Donaldson, popularly known as MrBeast, has waded into a bizarre online debate over the weekend involving a hypothetical fight between 100 men and one gorilla.
What Happened: On Monday, the 26-year-old YouTube megastar took to Elon Musk's X, formerly Twitter, and posted a photoshopped image of himself with gorillas, joking, "Need 100 men to test this, any volunteers?"
The animal rights group PETA (People for the Ethical Treatment of Animals) quickly rebuked him, responding: "100 men vs. a gorilla? Maybe try 100 reasons to leave animals out of your content instead…"
See Also:&nbsp;<a href="https://www.benzinga.com/tech/25/01/43325058/mrbeasts-net-worth-hits-1-billion-but-in-2023-he-promised-to-give-away-all-his-money-what-drives-the-youtubers-philanthropy" target="_blank" rel="noreferrer noopener">MrBeast's Net Worth Hits $1 Billion—But In 2023, He Promised To ‘Give Away' All His Money. What Drives The YouTuber's Philanthropy?</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">100 men vs. a gorilla? Maybe try 100 reasons to leave animals out of your content instead…
&mdash; PETA (@peta) <a href="https://twitter.com/peta/status/1916932465589162414?ref_src=twsrc%5Etfw">April 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The online debate — originally born in Reddit Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) r/whowouldwin forum in 2020 — resurfaced last week and has since spread across X, TikTok, and Facebook, <a href="https://www.usatoday.com/story/tech/2025/04/28/100-men-versus-1-gorilla/83326345007/">reported</a> USA Today.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It&#8217;s Important: MrBeast currently has an <a href="https://www.benzinga.com/personal-finance/25/04/44937545/mrbeast-net-worth-how-much-is-youtubes-biggest-creator-worth-in-april-2025">estimated net worth of $1 billion</a>, per Celebrity Net Worth. This valuation includes income from his vast YouTube presence, his snack brand Feastables, merchandise sales, lucrative sponsorships, and a <a href="https://www.benzinga.com/media/25/02/43996522/mrbeast-lost-millions-on-amazons-beast-games-now-hes-looking-to-raise-hundreds-of-millions-to-take-his-brand-to-the-next-level">major content deal</a> with Amazon.com.
According to Forbes, Donaldson brought in approximately $85 million in 2024 from content creation and brand deals alone.
He has stated in interviews that his total revenue across all ventures falls between $600 million and $700 million annually, with the majority funneled back into producing content, scaling operations, and expanding his team.
Photo Courtesy: Joe Seer On Shutterstock.com
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43078570/mrbeast-unhappy-with-billionaires-silence-on-feeding-the-hungry-after-overwhelming-interest-about-tiktok-purchase-when-i-fundraise-its-crickets" target="_blank" rel="noreferrer noopener">MrBeast Unhappy With Billionaires&#8217; Silence On Feeding The Hungry After Overwhelming Interest About TikTok Purchase: ‘When I Fundraise It&#8217;s Crickets&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"> </a>

Entertainment

RDDT

MrBeast Sparks Outrage With '100 Men Vs Gorilla' Post On Elon Musk's X — PETA Claps Back: 'Try 100 Reasons To Leave Animals...'

Five Star (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSBC#NASDAQ">FSBC</a>) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.59 by 5.08 percent. This is unchanged from the same period last year. The company reported quarterly sales of $35.34 million which beat the analyst consensus estimate of $34.20 million by 3.32 percent. This is a 23.65 percent increase over sales of $28.58 million the same period last year.

FSBC

Five Star Q1 EPS $0.62 Beats $0.59 Estimate, Sales $35.34M Beat $34.20M Estimate

In a bid to navigate the impending U.S. tariffs, South Africa and several other countries have been reportedly seeking advice from Goldman Sachs since late February.
What Happened: South African officials have been consulting with Goldman Sachs to devise strategies to mitigate the impact of the looming tariffs and appease President Donald Trump. The country was reportedly advised by Goldman that everything comes down to Trump's feelings. 
The bank recommended that South Africa consider revising certain laws, including one requiring Black ownership in some companies and another permitting the government to seize land from landowners to address racial disparities, <a href="https://www.wsj.com/finance/goldman-sachs-offers-advice-on-tariffs-to-countries-scrambling-to-please-trump-a138835f">reported </a>The Wall Street Journal.
Goldman Sachs did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment. 
Despite the advice from Goldman Sachs, a spokesperson for President Cyril Ramaphosa stated that the recommendations &#8220;would&nbsp;not have found favor with&nbsp;the government,&#8221; which is committed to addressing the imbalances of apartheid.
Goldman Sachs&#8217; advice is not limited to South Africa, as it has also been advising other nations, including France, Saudi Arabia, and Japan,&nbsp;on negotiating with the Trump&nbsp;administration. The Japanese government was reportedly reluctant to alter its tax policies solely to satisfy the administration. Countries are seeking advice from Wall Street banks on handling Trump's global trade war, with bankers warning that negotiations may involve unrelated political or symbolic concessions.
However, White House spokesperson Kush Desai stated that trading partners keen on negotiating a deal with Trump must &#8220;reduce the tariff and non-monetary barriers&#8221; causing the U.S. trade deficit, adding that any outside advice to the contrary is &#8220;pure speculation.&#8221;
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/04/45047682/texas-manufacturing-sentiment-worsens-to-lowest-reading-since-pandemic-from-tariff-driven-uncertainty" target="_blank" rel="noreferrer noopener">Dallas Fed Flags Deepening Factory Gloom: Is Texas Warning Of Something Bigger?</a>
Why It Matters: The move by South Africa and other countries comes in the backdrop of <a href="https://www.benzinga.com/25/04/45038824/treasury-secretary-scott-bessent-says-its-up-to-china-to-de-escalate-trade-tensions-india-to-be-the-first-trade-deal-to-be-signed">escalating </a>trade tensions globally. On Monday, Treasury Secretary Scott Bessent called on China to de-escalate trade tensions, pointing out China's higher export rate to the U.S. as a key factor contributing to the current tariff imbalance.
Furthermore, Goldman Sachs had predicted that the U.S. tariffs on <a href="https://www.benzinga.com/25/04/45033064/16-million-chinese-jobs-under-threat-amid-escalating-us-china-trade-war-predicts-goldman-sachs">Chinese imports</a> could put up to 16 million jobs in China at risk, particularly in the manufacturing sector, highlighting a gravity of the situation. This global context underscores the significance of the U.S. trading partners&#8217; consultations with Goldman Sachs and other Wall Street bankers as the countries seeks to protect its own economic interests.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/events/25/04/44971154/trump-fails-to-impress-americas-young-shows-poll-as-they-still-favor-biden-only-15-think-us-on-right-track" target="_blank" rel="noreferrer noopener">Trump Fails To Impress America&#8217;s Young, Shows Poll As They Still Favor Biden — Only 15% Think US On Right Track &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Want a Trade Deal? Keep Trump Happy, Goldman Sachs Reportedly Tells Countries

Solaris Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.12 by 66.67 percent. This is a 25 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $126.33 million which beat the analyst consensus estimate of $113.24 million by 11.57 percent. This is a 86.08 percent increase over sales of $67.89 million the same period last year.

Solaris Energy Q1 Adj. EPS $0.20 Beats $0.12 Estimate, Sales $126.33M Beat $113.24M Estimate

Cementos Pacasmayo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAC#NYSE">CPAC</a>) reported quarterly earnings of $0.16 per share. This is a 1.25 percent increase over earnings of $0.16 per share from the same period last year. The company reported $134.78 million in sales this quarter. This is a 6.23 percent increase over sales of $126.87 million the same period last year.

CPAC

Cementos Pacasmayo Q1 EPS $0.16 Up From $0.16 YoY, Sales $134.78M Up From $126.87M YoY

Press Releases

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Comments

X4 Pharmaceuticals

空売り

X4 Pharmaceuticals (NASDAQ:XFOR) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル